MEDICURE REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER EN MEDICURE REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021
Friday, August 27, 2021
WINNIPEG, MB, Aug. 27, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021.
Quarter Ended June 30, 2021 Highlights:
- Recorded total net revenue from the sale of products of $5.09 million during the second quarter ended June 30, 2021 compared to $2.68 million for the second quarter ended June 30, 2020;
- Recorded total net revenue from the sale of AGGRASTAT® of $2.8 million during the second quarter ended June 30, 2021compared to $2.6 million for the second quarter ended June 30, 2020;
- Net loss for the second quarter ended June 30, 2021 was $639,000 compared to net income of $19,000 for the second quarter ended June 30, 2020;
- Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA1) for the second quarter ended June 30, 2021 was $158,000 compared to adjusted EBITDA of $263,000 for the second quarter ended June 30, 2020
Financial Results
Net revenues for the three months ended June 30, 2021 were $5.09 million compared to $2.68 million for the three months ended June 30, 2020. Net revenues from AGGRASTAT® for the three months ended June 30, 2021 were $2.8 million compared to $2.6 million for the three months ended June 30, 2020. ZYPITAMAG® contributed $403,000 for the three months ended June 30, 2021compared to $103,000 for the three months ended June 30, 2020. Marley Drug™, which was acquired in December 2020, contributed $1.87 million for the three months ended June 30, 2021. Additionally, sodium nitroprusside (SNP), contributed $22,000, during the three months ended June 30, 2021, compared to $17,000 during the three months ended June 30, 2020.
Net revenues for the six months ended June 30, 2021 were $10.02 million compared to $5.3 million for the six months ended June 30, 2020. Net revenues from AGGRASTAT® for the six months ended June 30, 2021 were $5.4 million compared to $5.3 million for the six months ended June 30, 2020. ZYPITAMAG® contributed $564,000 for the six months ended June 30, 2021 compared to $266,000 for the six months ended June 30, 2020. Marley Drug™ contributed $3.97 million for the six months ended June 30, 2021. Additionally, SNP contributed $70,000, during the six months ended June 30, 2021, compared to $48,000 for the six months ended June 30, 2020.
Despite the impact from COVID-19, the volume of AGGRASTAT® sold in Q2 2021 was consistent with demand in Q2 2020. The Company continues to show strong patient market share with AGGRASTAT®, and demand from hospitals, driven by the Company's sales and marketing team. There was an increase in demand for ZYPITAMAG®, which was facilitated by sale through Marley Drug™ and the Company expects growth in ZYPITAMAG® revenues going forward. Marley Drug™ sales remain consistent, and the Company expects growth in sales as marketing is expanded.
Adjusted EBITDA for Q2 2021 was $158,000 compared to $31,000 for Q1 2021 and compared to $263,000 for Q2 2020. The decrease in adjusted EBITDA for Q2 2021 is the result of changes in research and development spending and fluctuating costs as the company works to integrate and optimize the Marley Drug™ operation.
Adjusted EBITDA for the six months ended June 30, 2021 was $189,000 compared to negative $1.02 million for the six months ended June 30, 2020. The improvement in adjusted EBITDA for the six months ended June 30, 2021 is the result rising ZYPITAMAG® sales, reduction of operating costs, and net revenue from the Marley Drug™ acquisition.
Net loss for the three months ended June 30, 2021 was $639,000 or $0.06 per share compared to net income of $19,000 or $0.00 per share for the three months ended June 30, 2020. The change in the net loss for the three months ended June 30, 2021 is the result of changes in research and development spending and fluctuating costs as the company works to integrate and optimize the Marley Drug™ operation.
Net loss for the six months ended June 30, 2021 was $1.688 million or $0.16 per share compared to $1.445 million or $0.13 per share for the six months ended June 30, 2020. The change in the net loss for the six months ended June 30, 2021 is the higher amortization expense as a result of the Marley Drug™ acquisition, partially offset by net revenue from the Marley Drug™ acquisition.
At June 30, 2021, the Company had unrestricted cash totaling $2.46 million down from $2.716 million of unrestricted cash held as of December 31, 2020. Cash flows provided from operating activities for the six months ended June 30, 2021 totaled $682,000compared to $1.793 million used for the six months ended June 30, 2020
All amounts referenced herein are in Canadian dollars unless otherwise noted.
Notes
(1) The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted for non–cash and other unusual items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three and six months ended June 30, 2021 and 2020 results prepared using IFRS, do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies.
Conference Call Info:
Topic: Medicure's Q2 2021 Results
Call date: Monday, August 30, 2021
Time: 7:30 AM Central Time (8:30 AM Eastern Time)
Canada toll: 1 (416) 764-8659
North American toll-free: 1 (888) 664-6392
Passcode: not required
Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: https://www.medicure.com/investors
You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event on the Company's website.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply mail order drug program serving 49 of 50 states, Washington D.C. and Puerto Rico. Marley Drug™ is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, refer to the full Prescribing Information. For additional information about ZYPITAMAG®, refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit:
https://medicure.mediaroom.com/alerts